Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Sinovac Biotech ( (SVA) ) just unveiled an update.
On May 16, 2025, Sinovac Biotech Ltd. received a notification from Nasdaq regarding its non-compliance with listing rules due to the late filing of its 2024 Annual Report. The company has until July 15, 2025, to submit a compliance plan and is in the process of selecting a new independent accounting firm after the resignation of Grant Thornton. This situation could impact Sinovac’s Nasdaq listing status and requires timely resolution to maintain investor confidence.
Spark’s Take on SVA Stock
According to Spark, TipRanks’ AI Analyst, SVA is a Neutral.
Sinovac Biotech’s overall score reflects its strong liquidity and balance sheet, offset by poor financial performance and lack of earnings. The technical indicators suggest neutrality, and the valuation appears unattractive due to the negative P/E ratio.
To see Spark’s full report on SVA stock, click here.
More about Sinovac Biotech
Sinovac Biotech Ltd. is a China-based biopharmaceutical company specializing in the research, development, manufacturing, and commercialization of vaccines for human infectious diseases. Its product portfolio includes vaccines for COVID-19, hepatitis A, enterovirus 71, influenza, and other diseases. Sinovac’s COVID-19 vaccine, CoronaVac, is approved in over 60 countries, and the company is a key supplier of influenza vaccines to the Chinese government.
Average Trading Volume: 8,227
Technical Sentiment Signal: Hold
Current Market Cap: $460.3M
Learn more about SVA stock on TipRanks’ Stock Analysis page.